johnson & Johnson said late Thursday that its single-shot COVID-19 vaccine generated strong, consistent activity against delta and other highly prevalent variants.
data showed that the permanence of the immune response lasted at least eight months, the US-based healthcare company said, adding that its vaccine was 85% effective and could also help prevent hospitalization and death.
“The current data from the eight months studied so far shows that the single-shot Johnson & Johnson COVID-19 vaccine produces a strong neutralizing antibody response that does not subside, rather, we observe improvement over time. Mathai Maimon, Head of Research and Development in the Drugs Business of Jammu and Kashmir, said in the statement.
The COVID-19 vaccine produced neutralizing antibody activity against the delta variant, which was first identified in India, at a level higher than that observed for the beta variant, which was first detected. South Africa, the company said.
J&J has submitted the data as a preprint to the website bioRxiv prior to peer review.
data showed that the permanence of the immune response lasted at least eight months, the US-based healthcare company said, adding that its vaccine was 85% effective and could also help prevent hospitalization and death.
“The current data from the eight months studied so far shows that the single-shot Johnson & Johnson COVID-19 vaccine produces a strong neutralizing antibody response that does not subside, rather, we observe improvement over time. Mathai Maimon, Head of Research and Development in the Drugs Business of Jammu and Kashmir, said in the statement.
The COVID-19 vaccine produced neutralizing antibody activity against the delta variant, which was first identified in India, at a level higher than that observed for the beta variant, which was first detected. South Africa, the company said.
J&J has submitted the data as a preprint to the website bioRxiv prior to peer review.
.